<DOC>
	<DOCNO>NCT01210495</DOCNO>
	<brief_summary>The study design demonstrate axitinib plus best supportive care superior placebo plus best supportive care prolong survival patient advance hepatocellular carcinoma .</brief_summary>
	<brief_title>Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<criteria>Locally advanced metastatic HCC Failure one prior antiangiogenic therapy include sorafenib , bevacizumab brivanib . ChildPugh Class A B ( score 7 ) disease . Prior treatment advance HCC one prior firstline systemic therapy . Any prior local therapy within 2 week start study treatment . Presence hepatic encephalopathy and/or clinically relevant ascites . Presence main portal vein invasion HCC .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hepatocellular Carcinoma</keyword>
</DOC>